These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30591175)

  • 61. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
    Suh YJ; Lee HJ; Kim YJ; Kim KG; Kim H; Jeon YK; Kim YT
    Lung Cancer; 2018 Sep; 123():52-59. PubMed ID: 30089595
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prediction of EGFR mutations by conventional CT-features in advanced pulmonary adenocarcinoma.
    Chen Y; Yang Y; Ma L; Zhu H; Feng T; Jiang S; Wei Y; Wang T; Sun X
    Eur J Radiol; 2019 Mar; 112():44-51. PubMed ID: 30777218
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma.
    Qiu X; Yuan H; Sima B
    Thorac Cancer; 2019 Feb; 10(2):170-174. PubMed ID: 30516345
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MRI-Based Radiomics Nomogram as a Potential Biomarker to Predict the EGFR Mutations in Exon 19 and 21 Based on Thoracic Spinal Metastases in Lung Adenocarcinoma.
    Cao R; Dong Y; Wang X; Ren M; Wang X; Zhao N; Yu T; Zhang L; Luo Y; Cui EN; Jiang X
    Acad Radiol; 2022 Mar; 29(3):e9-e17. PubMed ID: 34332860
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A new predictive scoring system based on clinical data and computed tomography features for diagnosing
    Cao Y; Xu H
    Curr Oncol; 2018 Apr; 25(2):e132-e138. PubMed ID: 29719437
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy.
    Choi CM; Kim MY; Lee JC; Kim HJ
    Radiology; 2014 Feb; 270(2):574-82. PubMed ID: 24086072
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The effective mutation of epidermal growth factor receptor in synchronous multiple primary lung cancers: study of clinical, radiographic and pathological factors].
    Wang YJ; Feng H; Ma SR; Wang YC; Liu YY; Bai HJ; Zhao L
    Zhonghua Yi Xue Za Zhi; 2019 Aug; 99(29):2297-2301. PubMed ID: 31434406
    [No Abstract]   [Full Text] [Related]  

  • 68. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
    Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
    PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas.
    Tomita M; Ayabe T; Chosa E; Kawagoe K; Nakamura K
    Asian Pac J Cancer Prev; 2014; 15(24):10627-30. PubMed ID: 25605150
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Correlation between the new lung adenocarcinoma classification and epidermal growth factor receptor mutation].
    Zhang XD; Liu DR
    Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Aug; 50(4):640-644. PubMed ID: 30122764
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
    Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
    Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
    [TBL] [Abstract][Full Text] [Related]  

  • 72. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.
    Zhang H; Cai W; Wang Y; Liao M; Tian S
    Int J Clin Oncol; 2019 Jun; 24(6):649-659. PubMed ID: 30835006
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
    Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
    Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
    Zhang T; Wang J; Su Y; Chen X; Yan Q; Li Q; Sun L; Wang Y; Er P; Pang Q; Wang P
    Oncotarget; 2017 Jun; 8(25):40594-40605. PubMed ID: 28380449
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.
    Fan X; Liu B; Xu H; Yu B; Shi S; Zhang J; Wang X; Wang J; Lu Z; Ma H; Zhou X
    Hum Pathol; 2013 Aug; 44(8):1499-507. PubMed ID: 23465272
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.
    Pan YQ; Shi WW; Xu DP; Xu HH; Zhou MY; Yan WH
    Chin Med Sci J; 2014 Sep; 29(3):156-61. PubMed ID: 25264883
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.
    Liu Y; Kim J; Balagurunathan Y; Hawkins S; Stringfield O; Schabath MB; Li Q; Qu F; Liu S; Garcia AL; Ye Z; Gillies RJ
    Med Phys; 2018 Jun; 45(6):2518-2526. PubMed ID: 29624702
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.